ASA
PTGX icon

Axxion S.A.’s Protagonist Therapeutics PTGX Stock Holding History

Axxion S.A.’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$184K Buy
+1,500
New +$157K 0.01% 438

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Axxion S.A.'s PTGX Position: Q2 2026 in Review

Axxion S.A. opened a new position in Protagonist Therapeutics (PTGX) in Q2 2026: 1,500 shares worth $184K. The stake represents 0.01% of the portfolio and ranks #438 among its holdings.

299 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Axxion S.A. held 1,500 shares of Protagonist Therapeutics worth $184K as of Q2 2026.
  • Protagonist Therapeutics was a new Axxion S.A. position in Q2 2026.
  • Protagonist Therapeutics made up 0.01% of Axxion S.A.'s portfolio in Q2 2026, its #438 holding.
  • 299 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Axxion S.A.'s 13F filing for Q2 2026, filed 14 Aug 2026.